Education
About Us
Working with TipRanks
Follow Us
Theralase Technologies (TSE:TLT)
:TLT
RESEARCH TOOLSreports
Earnings Data
Report Date
Sep 01, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
>-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 29, 2025
|% Change Since: -14.29%
|Next Earnings Date:Sep 01, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a company at a pivotal stage, achieving strategic milestones in its clinical studies and planning significant pipeline expansion. However, financial challenges, including declining revenues and increased expenses, present ongoing hurdles.Company Guidance
During the first quarter of 2025, Theralase Technologies reported nominal revenues of CAD 91,000 from its Cool Laser Therapy systems, a decrease from CAD 175,000 the previous year, as the company prioritized its bladder cancer clinical study. Gross margin was CAD 13,000, representing 15% of revenue. Operating expenses included CAD 68,000 in selling expenses, CAD 555,000 in administrative expenses (a 9% increase), and CAD 878,000 in research and development expenses (a 16% increase). The net loss for the quarter was CAD 1.47 million, including CAD 256,000 in non-cash charges. Theralase also closed private placements totaling CAD 730,000 in the first half of 2025 and has raised nearly CAD 7.5 million over the past 24 months. The company is exploring a U.S. uplist and institutional financing to support its drug and device divisions and plans to initiate new clinical studies in multiple cancer and viral indications by early 2026.Completion of Clinical Study Enrollment
Theralase is set to complete enrollment in a critical bladder cancer study by summer 2025, a major milestone that positions the company for regulatory submissions in 2026.
Expansion into New Indications
Theralase plans to expand its clinical pipeline into 9 high-value indications, including various cancers and the Herpes Simplex virus, with plans to start new clinical studies in early 2026.
Strong Safety and Efficacy Profile
The Study II for bladder cancer has shown a 62% complete response rate with no serious adverse events related to the treatment, highlighting its safety and efficacy.
Significant Capital Raised
Theralase successfully raised nearly $7.5 million over 24 months through private placements, with plans for further U.S. institutional fundraising.
TSE:TLT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:TLT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 29, 2025 | C$0.21 | C$0.20 | -4.76% |
Mar 12, 2025 | C$0.24 | C$0.22 | -8.33% |
Nov 27, 2024 | C$0.30 | C$0.21 | -30.00% |
Aug 12, 2024 | C$0.20 | C$0.18 | -10.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Theralase Technologies (TSE:TLT) report earnings?
Theralase Technologies (TSE:TLT) is schdueled to report earning on Sep 01, 2025, TBA Not Confirmed.
What is Theralase Technologies (TSE:TLT) earnings time?
Theralase Technologies (TSE:TLT) earnings time is at Sep 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:TLT EPS forecast?
TSE:TLT EPS forecast for the fiscal quarter 2025 (Q2) is >-0.01.